Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,630 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07321145Recruiting
Robot vs. Endoscopic Breast-Conserving Surgery
This trial looks back at medical records to compare two types of breast-conserving surgery (robot-assisted vs. endoscopic) for women with early-stage breast cancer. It's for women who are good candidates for keeping their breast and who want a less invasive surgical option.
Guangzhou, GuangdongAges 18–80 - NCT07322627Recruiting
Esophageal cancer genetics and treatment outlook study
This study looks at a specific gene (ALDH2) in people with esophageal cancer to see if it affects how well they respond to treatment. It may help doctors better predict outcomes and personalize care.
TaipeiAges 18–99 - NCT07327021RecruitingPhase 2
MRI-Guided treatment reduction for stage 2-3 triple-negative breast cancer
This trial tests if using MRI scans can safely reduce the amount of chemotherapy and immunotherapy needed before surgery for triple-negative breast cancer. All patients will receive the standard KEYNOTE-522 regimen, but the treatment may be tailored based on MRI results.
Tel AvivAges 18 years+ - NCT07327970Recruiting
AI test to predict breast cancer treatment response
This study tests whether an AI tool can predict how well breast cancer responds to chemotherapy given before surgery. Your tumor sample from a needle biopsy will be analyzed to see if the AI's prediction matches your actual treatment outcome.
IncheonAges 18 years+ - NCT07333066RecruitingPhase 3
Adding chemotherapy when first treatment response is limited
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
BayonneAges 18 years+ - NCT07333274RecruitingPhase 3
Radiation plus nimotuzumab for head and neck cancer
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
Shandong, ProvinceAges 18 years+ - NCT07335354Recruiting
Decision tool for breast reconstruction after mastectomy
This study is testing a decision tool to help people who are thinking about breast reconstruction surgery after a mastectomy. The tool is designed to help you and your doctor make a more informed choice.
Basking Ridge, New JerseyAges 18 years+ - NCT07336446RecruitingPhase 1/Phase 2
Testing AZD9750 for metastatic prostate cancer with or without other drugs
This trial is for men with metastatic prostate cancer that has gotten worse despite treatment. It tests a new drug called AZD9750, given alone or with other cancer drugs, to see if it is safe and works well.
Duarte, CaliforniaAges 18 years+ - NCT07337876RecruitingPhase 2
Avoiding surgery for rectal cancer with precise radiation
This trial tests a new way to give high-dose radiation to rectal cancer tumors while avoiding the bladder and bowels. The goal is to cure the cancer without removing the rectum, so you may keep normal bowel function.
Tübingen, Baden-WurttembergAges 18 years+ - NCT07342283RecruitingPhase 2
QL1706 plus chemo before surgery for triple-negative breast cancer
This trial tests a combination of an immunotherapy drug (QL1706) plus standard chemotherapy given before surgery to shrink triple-negative breast cancer. The goal is to see if this approach helps remove the tumor more completely.
Nantong, JiangsuAges 18 years+ - NCT07342335Recruiting
Making research easier for cancer patients
This study aims to make it easier for people with cancer to take part in research by removing common barriers. It is open to adults receiving treatment at a specific hospital.
LiverpoolAges 18 years+ - NCT07343791RecruitingEarly Phase 1
DC-CIK cell therapy plus three drugs for advanced colorectal cancer
This trial tests a combination of immune cells (DC-CIK) and three cancer drugs (epaloliposide, vortexil, and regorafenib) as a third-line treatment for people with advanced colorectal cancer that has spread. It aims to see if this mix is safe and helps shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT07344311RecruitingPhase 1
CAR-T cell therapy for advanced prostate cancer
This trial tests a new immunotherapy called A-CAR032, which uses your own immune cells to attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07079631RecruitingPhase 1/Phase 2
Testing BNT314 with pumitamig and chemo for advanced colorectal cancer
This trial tests a new combination of drugs (BNT314 and pumitamig) plus chemotherapy for people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT05128825RecruitingPhase 2
Test drug azenosertib for platinum-resistant ovarian cancer
This Phase 2 trial tests azenosertib to treat platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. It looks for whether the drug can shrink tumors and improve outcomes in people whose cancer has returned after platinum chemotherapy.
Mobile, AlabamaAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Mobile, AlabamaAges 18 years+ - NCT07347951RecruitingPhase 2
New drug combo for rectal cancer patients who want to save their anus
This trial tests a combination of short-course radiation, chemotherapy, and two targeted drugs (Serplulimab and Bevacizumab) for people with a specific type of rectal cancer. It aims to see if this treatment can help shrink the tumor enough to avoid surgery and keep the anus.
Wenzhou, ZhejiangAges 18–75 - NCT07349043RecruitingPhase 1
Spray chemotherapy for colon cancer spread in the belly
This trial tests a new way to give chemotherapy by spraying it into the belly during a minimally invasive surgery. It is for people whose colon or rectal cancer has spread inside the belly (peritoneal metastasis) but not to other organs.
Hangzhou, Other (Non U.s.)Ages 18–75 - NCT07349069RecruitingPhase 3
HRS-8080 vs. standard hormone therapy for early breast cancer
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
Nanjing, JiangsuAges 18–75 - NCT07353723RecruitingPhase 2
Combination therapy for advanced tonsil cancer
This trial tests a combination of two targeted drugs (nimotuzumab and toripalimab) with chemotherapy for people with advanced tonsil cancer that can be surgically removed. The goal is to see if this approach works better than standard treatment.
Shanxi, ProvinceAges 18–80 - NCT07354022RecruitingPhase 3
Study of HRS-8080 with dalpiciclib for advanced breast cancer after hormone therapy fails
This trial tests a new combination of drugs (HRS-8080 and dalpiciclib) for women with advanced or metastatic breast cancer that has stopped responding to initial hormone therapy after surgery. It aims to see if this combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07354100RecruitingPhase 1/Phase 2
Lactulose to boost gut health during immunotherapy
This study tests whether a simple sugar syrup called lactulose can improve gut health and make immunotherapy work better for certain cancers. Lactulose is taken by mouth along with your regular immunotherapy.
Chicago, IllinoisAges 18 years+ - NCT07359235RecruitingPhase 1
KD01 for bladder cancer: a safety and early efficacy trial
This trial tests a new drug called KD01, which is given directly into the bladder through a catheter (intravesical instillation) for bladder cancer. It aims to see if the drug is safe and tolerable, and if it may help slow or stop the cancer.
Wuhan, HubeiAges 18–75 - NCT07359989Recruiting
Leucine plus chemoradiation before surgery for rectal cancer
This trial tests whether adding leucine (a simple amino acid) to standard chemoradiation before surgery can help shrink rectal cancer and improve outcomes. It is for people with locally advanced rectal cancer that hasn't yet spread to other organs.
Hangzhou, ZhejiangAges 18–80
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,630 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.